Catherine Smith, MD

Catherine Smith, MD

Assistant Professor, Division of Hematology/Oncology, Department of Medicine, UCSF

Phone: 476-9553 (voice)
Box 1270, UCSF
San Francisco, CA 94143-1270

View on UCSF Profiles

Cancer Center Membership

Associate Member ยป Hematopoietic Malignancies


Yale University, CT, BS, 1998, Chemistry
Duke University, MD, 2002, Medicine

Professional Experience

  • 7/2002-6/2005
    Residency, Internal Medicine, Brigham and Women's Hospital, Harvard Medical School
  • 7/2005-6/2006
    Clinical Instructor, Department of Medicine, University of California at San Francisco
  • 7/2006-7/2009
    Fellow, Division of Hematology/Oncology, Department of Medicine, University of California at San Francisco
  • 8/2009-6/2011
    Adjunct Instructor, Division of Hematology/Oncology, Department of Medicine, University of California at San Francisco
  • 7/2011-present
    Assistant Professor, Division of Hematology/Oncology, Department of Medicine, University of California at San Francisco

Honors & Awards

  • 2010
    Leukemia and Lymphoma Society Special Fellow in Clinical Research Career Development Award
  • 2010
    European Hematology Association/American Society of Hematology Translational Research Training Program Award
  • 2009
    American Society of Hematology Research Training Award for Fellows, Finalist
  • 2002
    American Medical Women's Association, Inc. Janet M. Glasgow Memorial Achievement Citation Awarded to graduating women medical students who graduate in the top 10% of their class.
  • 2002
    E. E. Owen, M.D. Clinical Scholar Award Awarded to 2 graduating medical students for clinical excellence.
  • 2001
    William G. Anylan Scholarship Awarded to 4th year medical students deserving recognition based on academics, service to the medical school and commitment to the profession.
  • 2000
    Alpha Omega Alpha
  • 2000-2001
    Howard Hughes Medical Institute Research (HHMI) Medical Student Training Fellowship
  • 1998
    Cum Laude, Yale University
  • 1998
    Howard Douglass Moore Prize Awarded for excellence in the field of chemistry at Yale University.
  • 1998
    Michael T. Manzella Award Presented to the senior who through the qualities of kindness, dedication and courage most inspired classmates in Timothy Dwight College at Yale.
  • 1997
    National Institutes of Health (NIH) Summer Research Internship
  • 1996
    Howard Hughes Medical Institute (HHMI) Summer Research Fellowship

Selected Publications

  1. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. Cancer Discov. 2015 Jun; 5(6):668-79.
    View on PubMed
  2. Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. Eur J Med Chem. 2015 Apr 13; 94:123-31.
    View on PubMed
  3. A phase I study of targeted, dose-escalated intravenous busulfan in combination with Etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83.
    View on PubMed
  4. Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. Elife. 2014; 3.
    View on PubMed
  5. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. Cell Rep. 2014 Nov 20; 9(4):1333-48.
    View on PubMed
  6. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44.
    View on PubMed
  7. FLT3 inhibitors in AML: are we there yet? Curr Hematol Malig Rep. 2014 Jun; 9(2):174-85.
    View on PubMed
  8. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A. 2014 Apr 8; 111(14):5319-24.
    View on PubMed
  9. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar; 38(3):316-22.
    View on PubMed
  10. Disease diversity and FLT3 mutations. Proc Natl Acad Sci U S A. 2013 Dec 24; 110(52):20860-1.
    View on PubMed
  11. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 2013 Apr 18; 121(16):3165-71.
    View on PubMed
  12. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2013; 313-8.
    View on PubMed
  13. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012 May 10; 485(7397):260-3.
    View on PubMed
  14. Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia. Am Soc Clin Oncol Educ Book. 2012; 685-9.
    View on PubMed
  15. Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia. Clin Cancer Res. 2011 Nov 1; 17(21):6605-7.
    View on PubMed
  16. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Hematology Am Soc Hematol Educ Program. 2011; 2011:121-7.
    View on PubMed
  17. Cost-effectiveness of private umbilical cord blood banking. Obstet Gynecol. 2009 Oct; 114(4):848-55.
    View on PubMed

Go to UCSF Profiles, powered by CTSI